Pre-cessation nicotine replacement therapy: pragmatic randomized trial
Version of Record online: 7 JUN 2010
© 2010 The University of Auckland
Volume 105, Issue 8, pages 1474–1483, August 2010
How to Cite
Bullen, C., Howe, C., Lin, R.-B., Grigg, M., Laugesen, M., McRobbie, H., Glover, M., Walker, N., Wallace-Bell, M., Whittaker, R. and Rodgers, A. (2010), Pre-cessation nicotine replacement therapy: pragmatic randomized trial. Addiction, 105: 1474–1483. doi: 10.1111/j.1360-0443.2010.02989.x
- Issue online: 9 JUL 2010
- Version of Record online: 7 JUN 2010
- Submitted 3 September 2009; initial review completed 18 November 2009; final version accepted 17 February 2010
- clinical trial;
- nicotine replacement therapy;
Aims To determine the effectiveness of 2 weeks' pre-cessation nicotine patches and/or gum on smoking abstinence at 6 months.
Design Pragmatic randomized controlled trial.
Setting New Zealand.
Participants Eleven hundred adult, dependent smokers who called the New Zealand Quitline between March 2006 and May 2007 for support to stop smoking were randomized to 2 weeks of nicotine patches and/or gum prior to their target quit day followed by usual care (8 weeks of patches and/or gum plus support calls from a Quitline adviser), or to usual care alone.
Measurements The primary outcome was self-reported 7-day point prevalence smoking abstinence 6 months after quit day. Secondary outcomes included continuous abstinence, cotinine-verified abstinence, daily cigarette consumption, withdrawal symptoms and adverse events.
Findings Six months after quit day 125 (22.7%) participants in the pre-cessation group and 116 (21.0%) in the control group reported 7-day point prevalence abstinence (relative risk 1.08 95% CI: 0.86, 1.35, P = 0.4, risk difference 1.7%, 95% CI: −3.2%, 6.6%). However, when pooled in a meta-analysis with other pre-cessation trials a moderate benefit of about a one-quarter increase in cessation rates was evident. There was no difference in adverse events between groups.
Conclusions In this, the largest pre-cessation NRT trial to date, using NRT 2 weeks before the target quit day was safe and well tolerated but offered no benefit over usual care. However, in conjunction with previous pre-cessation trials there appears to be a moderate benefit, but not as large as that seen in most smaller trials.